ANEMOCYTE

Serial Number 79211373
Registration 5440621
700

Registration Progress

Application Filed
Feb 6, 2017
Under Examination
Approved for Publication
Jan 23, 2018
Published for Opposition
Jan 23, 2018
Registered
Apr 10, 2018

Trademark Image

ANEMOCYTE

Basic Information

Serial Number
79211373
Registration Number
5440621
Filing Date
February 6, 2017
Registration Date
April 10, 2018
Published for Opposition
January 23, 2018
Drawing Code
5

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 10, 2018
Registration
Registered
Classes
005 042

Rights Holder

ANEMOCYTE S.R.L.

16
Address
Via Roberto Lepetit, 34
GERENZANO (VA) I-21040
IT

Ownership History

ARETA INTERNATIONAL S.R.L.

Original Applicant
16
IT

ANEMOCYTE S.R.L.

Owner at Publication
16
IT

ANEMOCYTE S.R.L.

Original Registrant
16
GERENZANO (VA) IT

Legal Representation

Attorney
Brian A. Tollefson

USPTO Deadlines

Next Deadline
977 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-04-10)
Due Date
April 10, 2028
Grace Period Ends
October 10, 2028

Application History

46 events
Date Code Type Description Documents
Jun 6, 2025 PR75 O POST REGISTRATION ACTION MAILED - SEC. 71 & 15 Loading...
May 15, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
May 15, 2025 EROP I TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED Loading...
May 15, 2025 EWOR I TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED Loading...
May 15, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 15, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Dec 16, 2024 PR75 O POST REGISTRATION ACTION MAILED - SEC. 71 & 15 Loading...
Nov 20, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Apr 9, 2024 ES75 I TEAS SECTION 71 & 15 RECEIVED Loading...
Apr 10, 2023 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Oct 24, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 24, 2022 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Oct 24, 2022 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
Oct 24, 2022 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Oct 24, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Oct 24, 2022 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Oct 24, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 9, 2021 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Aug 11, 2018 FINV P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Jul 16, 2018 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Jul 16, 2018 FIMP P FINAL DISPOSITION PROCESSED Loading...
Jul 10, 2018 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 10, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Feb 22, 2018 ADCH M CHANGE OF NAME/ADDRESS REC'D FROM IB Loading...
Feb 10, 2018 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Jan 23, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 23, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 3, 2018 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Jan 3, 2018 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Jan 3, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 11, 2017 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 11, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 11, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 11, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Oct 20, 2017 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 20, 2017 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 4, 2017 RFNT P REFUSAL PROCESSED BY IB Loading...
Jul 18, 2017 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Jul 18, 2017 RFRR P REFUSAL PROCESSED BY MPU Loading...
Jul 12, 2017 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Jul 12, 2017 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Jul 11, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 8, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 8, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 7, 2017 LIMI I LIMITATION FROM ORIGINAL APPLICATION ENTERED Loading...
Jul 6, 2017 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues ] for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues ] for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription ] medicines, namely, [ pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, ] vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes ] ; biological reagents for medical use; medicinal products based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical [ and veterinary ] purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; [ biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; ] [ products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; ] products for personalized medicine made of [ autologous cells or proteins or ] nucleid acids derived from individual genomic sequences; [ preparations made up of cells for medical or clinical use; ] preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]
Class 042
Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes

Additional Information

Design Mark
The mark consists of the following: the stylized term "ANEMOCYTE" with the letters "ANEM" and "YTE" appearing in dark grey, and the letters "OC" merged and appearing in light blue, green, blue and light grey.
Color Claim
The color(s) light blue, green, blue, light grey and dark grey is/are claimed as a feature of the mark.

Classification

International Classes
005 042